Overall, the FDA prediction method led us to conclude that CD19hi CD27– “atypical naive” B cell, CD16+ monocyte and plasmablast proportions, and absolute number of basophils were effective in discriminating inactive SLE individuals from most of highly active patients, undergoing hemodialysis (aHD>4) or not (aLN). Here, CD27 is linked to systemic lupus erythematosus.